Company news

Nexalis Therapeutics Limited news in 2024

Nexalis Therapeutics Limited's news releases, calls and decks from 2024, newest first.

View company

Shareholder Update

December 19, 2024

Issue of Securities Following General Meeting Approval

December 15, 2024

Ethics Approval for Phase 2 Clinical Trial of IRX-211

November 14, 2024

Sep24 Appendix 4C Cash Flow Report

October 31, 2024

Sep24 Quarterly Activities Report

October 31, 2024

$38.5m Funding to Fully Fund Clinical Development Plans

October 17, 2024

Issue of Shares to CEO in Lieu of Accrued Salary

October 2, 2024

Jun24 Quarterly Activities Report

July 31, 2024

Jun24 Appendix 4C Cash Flow Report

July 31, 2024

Mar24 Appendix 4C Cash Flow Report

April 30, 2024

Mar24 Quarterly Activities Report

April 30, 2024

Dec23 Quarterly Activities Report

January 16, 2024

Dec23 Appendix 4C Cash Flow Report

January 16, 2024

IRX211 - Targeted Pain Indication Nomination - BTcP

January 10, 2024

Decks in 2024